Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers

Frank Jessen; Steffen Wolfsgruber; Luca Kleineindam; Annika Spottke; Slawek Altenstein; Claudia Bartels; Moritz Berger; Frederic Brosseron; Marcel Daamen; Martin Dichgans; Laura Dobisch; Michael Ewers; Friederike Fenski; Klaus Fliessbach; Silka D. Freiesleben; Wenzel Glanz; Doreen Görß; Selim Gürsel; Daniel Janowitz; Ingo Kilimann; Xenia Kobeleva; Andrea Lohse; Franziska Maier; Coraline Metzger; Matthias Munk; Lukas Preis; Carolin Sanzenbacher; Eike Spruth; Boris Rauchmann; Ruth Vukovich; Renat Yakupov; Anne Sophie Weyrauch; Gabriel Ziegler; Matthias Schmid; Christoph Laske; Robert Perneczky; Anja Schneider; Jens Wiltfang; Stefan Teipel; Katharina Bürger; Josef Priller; Oliver Peters; Alfredo Ramirez; Henning Boecker; Michael T. Heneka; Michael Wagner; Emrah Düzel

doi:10.1002/alz.12674

Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers

Frank Jessen, Steffen Wolfsgruber, Luca Kleineindam, Annika Spottke, Slawek Altenstein, Claudia Bartels, Moritz Berger, Frederic Brosseron, Marcel Daamen, Martin Dichgans, Laura Dobisch, Michael Ewers, Friederike Fenski, Klaus Fliessbach, Silka D. Freiesleben, Wenzel Glanz, Doreen Görß, Selim Gürsel, Daniel Janowitz, Ingo KilimannXenia Kobeleva, Andrea Lohse, Franziska Maier, Coraline Metzger, Matthias Munk, Lukas Preis, Carolin Sanzenbacher, Eike Spruth, Boris Rauchmann, Ruth Vukovich, Renat Yakupov, Anne Sophie Weyrauch, Gabriel Ziegler, Matthias Schmid, Christoph Laske, Robert Perneczky, Anja Schneider, Jens Wiltfang, Stefan Teipel, Katharina Bürger, Josef Priller, Oliver Peters, Alfredo Ramirez, Henning Boecker, Michael T. Heneka, Michael Wagner, Emrah Düzel

Research output: Contribution to journal › Article › peer-review

67 Scopus citations

Abstract

Introduction: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. Methods: Cross-sectional and longitudinal data from the multicenter, memory clinic–based DELCODE study. Results: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD–A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO–A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group. Discussion: Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD-A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.

Original language	English
Pages (from-to)	487-497
Number of pages	11
Journal	Alzheimer's and Dementia
Volume	19
Issue number	2
DOIs	https://doi.org/10.1002/alz.12674
State	Published - Feb 2023
Externally published	Yes

Keywords

Alzheimer's disease
amyloid beta 42
apolipoprotein E
cerebrospinal fluid
longitudinal
magnetic resonance imaging
mild cognitive impairment
positron emission tomography
subjective cognitive decline
tau

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/alz.12674

Cite this

Jessen, F., Wolfsgruber, S., Kleineindam, L., Spottke, A., Altenstein, S., Bartels, C., Berger, M., Brosseron, F., Daamen, M., Dichgans, M., Dobisch, L., Ewers, M., Fenski, F., Fliessbach, K., Freiesleben, S. D., Glanz, W., Görß, D., Gürsel, S., Janowitz, D., ... Düzel, E. (2023). Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. Alzheimer's and Dementia, 19(2), 487-497. https://doi.org/10.1002/alz.12674

@article{c119ed764b784111aa3defcce63e4454,

title = "Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers",

abstract = "Introduction: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. Methods: Cross-sectional and longitudinal data from the multicenter, memory clinic–based DELCODE study. Results: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD–A+ cases (39.3\% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO–A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group. Discussion: Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD-A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.",

keywords = "Alzheimer's disease, amyloid beta 42, apolipoprotein E, cerebrospinal fluid, longitudinal, magnetic resonance imaging, mild cognitive impairment, positron emission tomography, subjective cognitive decline, tau",

author = "Frank Jessen and Steffen Wolfsgruber and Luca Kleineindam and Annika Spottke and Slawek Altenstein and Claudia Bartels and Moritz Berger and Frederic Brosseron and Marcel Daamen and Martin Dichgans and Laura Dobisch and Michael Ewers and Friederike Fenski and Klaus Fliessbach and Freiesleben, \{Silka D.\} and Wenzel Glanz and Doreen G{\"o}r{\ss} and Selim G{\"u}rsel and Daniel Janowitz and Ingo Kilimann and Xenia Kobeleva and Andrea Lohse and Franziska Maier and Coraline Metzger and Matthias Munk and Lukas Preis and Carolin Sanzenbacher and Eike Spruth and Boris Rauchmann and Ruth Vukovich and Renat Yakupov and Weyrauch, \{Anne Sophie\} and Gabriel Ziegler and Matthias Schmid and Christoph Laske and Robert Perneczky and Anja Schneider and Jens Wiltfang and Stefan Teipel and Katharina B{\"u}rger and Josef Priller and Oliver Peters and Alfredo Ramirez and Henning Boecker and Heneka, \{Michael T.\} and Michael Wagner and Emrah D{\"u}zel",

note = "Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's \& Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2023",

month = feb,

doi = "10.1002/alz.12674",

language = "English",

volume = "19",

pages = "487--497",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

Jessen, F, Wolfsgruber, S, Kleineindam, L, Spottke, A, Altenstein, S, Bartels, C, Berger, M, Brosseron, F, Daamen, M, Dichgans, M, Dobisch, L, Ewers, M, Fenski, F, Fliessbach, K, Freiesleben, SD, Glanz, W, Görß, D, Gürsel, S, Janowitz, D, Kilimann, I, Kobeleva, X, Lohse, A, Maier, F, Metzger, C, Munk, M, Preis, L, Sanzenbacher, C, Spruth, E, Rauchmann, B, Vukovich, R, Yakupov, R, Weyrauch, AS, Ziegler, G, Schmid, M, Laske, C, Perneczky, R, Schneider, A, Wiltfang, J, Teipel, S, Bürger, K, Priller, J, Peters, O, Ramirez, A, Boecker, H, Heneka, MT, Wagner, M & Düzel, E 2023, 'Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers', Alzheimer's and Dementia, vol. 19, no. 2, pp. 487-497. https://doi.org/10.1002/alz.12674

TY - JOUR

T1 - Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers

AU - Jessen, Frank

AU - Wolfsgruber, Steffen

AU - Kleineindam, Luca

AU - Spottke, Annika

AU - Altenstein, Slawek

AU - Bartels, Claudia

AU - Berger, Moritz

AU - Brosseron, Frederic

AU - Daamen, Marcel

AU - Dichgans, Martin

AU - Dobisch, Laura

AU - Ewers, Michael

AU - Fenski, Friederike

AU - Fliessbach, Klaus

AU - Freiesleben, Silka D.

AU - Glanz, Wenzel

AU - Görß, Doreen

AU - Gürsel, Selim

AU - Janowitz, Daniel

AU - Kilimann, Ingo

AU - Kobeleva, Xenia

AU - Lohse, Andrea

AU - Maier, Franziska

AU - Metzger, Coraline

AU - Munk, Matthias

AU - Preis, Lukas

AU - Sanzenbacher, Carolin

AU - Spruth, Eike

AU - Rauchmann, Boris

AU - Vukovich, Ruth

AU - Yakupov, Renat

AU - Weyrauch, Anne Sophie

AU - Ziegler, Gabriel

AU - Schmid, Matthias

AU - Laske, Christoph

AU - Perneczky, Robert

AU - Schneider, Anja

AU - Wiltfang, Jens

AU - Teipel, Stefan

AU - Bürger, Katharina

AU - Priller, Josef

AU - Peters, Oliver

AU - Ramirez, Alfredo

AU - Boecker, Henning

AU - Heneka, Michael T.

AU - Wagner, Michael

AU - Düzel, Emrah

PY - 2023/2

Y1 - 2023/2

N2 - Introduction: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. Methods: Cross-sectional and longitudinal data from the multicenter, memory clinic–based DELCODE study. Results: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD–A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO–A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group. Discussion: Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD-A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.

AB - Introduction: It is uncertain whether subjective cognitive decline (SCD) in individuals who seek medical help serves the identification of the initial symptomatic stage 2 of the Alzheimer's disease (AD) continuum. Methods: Cross-sectional and longitudinal data from the multicenter, memory clinic–based DELCODE study. Results: The SCD group showed slightly worse cognition as well as more subtle functional and behavioral symptoms than the control group (CO). SCD–A+ cases (39.3% of all SCD) showed greater hippocampal atrophy, lower cognitive and functional performance, and more behavioral symptoms than CO–A+. Amyloid concentration in the CSF had a greater effect on longitudinal cognitive decline in SCD than in the CO group. Discussion: Our data suggests that SCD serves the identification of stage 2 of the AD continuum and that stage 2, operationalized as SCD-A+, is associated with subtle, but extended impact of AD pathology in terms of neurodegeneration, symptoms and clinical progression.

KW - Alzheimer's disease

KW - amyloid beta 42

KW - apolipoprotein E

KW - cerebrospinal fluid

KW - longitudinal

KW - magnetic resonance imaging

KW - mild cognitive impairment

KW - positron emission tomography

KW - subjective cognitive decline

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=85128515174&partnerID=8YFLogxK

U2 - 10.1002/alz.12674

DO - 10.1002/alz.12674

M3 - Article

C2 - 35451563

AN - SCOPUS:85128515174

SN - 1552-5260

VL - 19

SP - 487

EP - 497

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 2

ER -

Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this